Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting

Neurology India

Volumn 57, Issue 4, 2009, Pages 418-423

  Singhal, B S ^a   Geeta, Sheth ^a   Hundalani, Shilpa G ^a   Menon, Suresh ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

Mitoxantrone; Multiple sclerosis; Novantrone

Indexed keywords

GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HAIR LOSS; HEART EJECTION FRACTION; HUMAN; HYPOKINESIA; INDIA; LEUKOPENIA; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NAUSEA AND VOMITING; RECURRENT DISEASE; SIDE EFFECT; TERTIARY HEALTH CARE; TREATMENT DURATION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; ANALGESICS; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 70349411720     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.55611     Document Type: Article

References (32)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911
2. Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: A placebo- controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025
3. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:1332-1338
4. Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, et al. Identifying and treating patients with suboptimal responses. Neurology 2004;63:S33-40
5. Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: A review. Clin Ther 2006;28:461-474
6. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: What is the risk and can we minimise it? Mult Scler 2009;15:505-508
7. Martinelli V. Leukemia risk with Mitoxantrone for multiple sclerosis (abstract). American Academy of Neurology 61st Annual Meeting, 2009. LB3.001
8. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
10. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846
11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
12. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489
13. Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stüve O, et al. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168:128-137
14. Kopadze T, Dehmel T, Hartung HP, Stüve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: A possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2006;63:1572-1578
15. Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63:S15-8
16. Rizvi SA, Zwibel H, Fox EJ. Mitoxantrone for multiple sclerosis in clinical practice. Neurology 2004;63:S25-7
17. Touchette DR, Durgin TL, Wanke LA, Goodkin DE. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther 2003;25:611-634
18. Buttinelli C, Clemenzi A, Borriello G, Denaro F, Pozzilli C, Fieschi C. Mitoxantrone treatment in multiple sclerosis: A 5-year clinical and MRI follow-up. Eur J Neurol 2007;14:1281-1287
19. Debouverie M, Taillandier L, Pittion-Vouyovitch S, Louis S, Vespignani H. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment. Mult Scler 2007;13:626-631
20. Hamzehloo A, Etemadifar M. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. Arch Iran Med 2007;10:59-64
21. Komori M, Tanaka M, Muramoto E, Ohno M, Matsumoto R, Murase N, et al. Mitoxantrone for the treatment of Japanese patients with multiple sclerosis. Rinsho Shinkeigaku 2007;47:401-406 (Pubitemid 47266145)
22. Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957-963
23. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14:663-670
24. Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006;253:1160-1164
25. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108
26. Coles AJ. CAMMS223 Study Group. Alemtuzumab Induces a Sustained Reduction in Disability in Patients with Relapsing Remitting Multiple Sclerosis. American Academy of Neurology. 61st Annual Meeting, 2009. p. 145
27. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, et al. for the AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405-415
28. Putzki N, Yaldizli O, Mäurer M, Kuckert S, Cursiefen S, Tettenborn B, et al. Natalizumab Reduces Clinical and MRI Disease Activity in Second Line Treatment of Relapsing Remitting Multiple Sclerosis: Results of a Multicenter Study. American Academy of Neurology. 61st Annual Meeting, 2009. p. 5-128
29. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. Lancet Neurol 2009;8:244-253
30. Mark S. Freedman, Harold L. Atkins, Marjorie Bowman, Canadian BMT Study Group. Neurological Recovery Following Treatment of Aggressive MS with Immunoablation and Autologous Stem Cell Transplantation. American Academy of Neurology, 61st Annual Meeting, 2009. p 02.145
31. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-913
32. Peak S, Tsao-Wei DD, Chamberlain MC. Mitoxantrone in secondary progressive multiple sclerosis: A review of toxicity in 41 patients. Therapy 2007;4:55-58